Posner--Schlossman syndrome (PSS) is characterized by unilateral anterior uveitis (AU), causing recurrent episodes of elevated intraocular pressure (IOP),[@bib1] especially in males. Many previous studies have reported the involvement of cytomegalovirus (CMV) in the pathogenesis of PSS.[@bib2]^--^[@bib8] For example, Chee et al.[@bib2] reported that 52.2% of suspected PSS patients were CMV-positive for aqueous humor (AH). Regarding the decrease of corneal endothelial cells in CMV-positive AU patients, several cytokines have been reported to be upregulated in the AH of these patients, but the mechanism of endothelial cell loss and the relationship between these upregulated cytokines are poorly understood; there is no effective treatment for preserving corneal endothelial cells.

TNF-α is one of the T-helper 1 (Th1) immune mediators that is reportedly upregulated in various types of uveitis.[@bib9] Especially in PSS eyes, it has been previously reported that the levels of aqueous TNF-α were significantly increased compared to control eyes (i.e., eyes without any complications), which could be related to the induction of inflammation in PSS patients.[@bib10]^--^[@bib13] Numerous studies have reported that TNF-α plays a role in corneal endothelial cell loss, because it induces apoptosis, cellular barrier dysfunction, and prolonged immune responses via induction of the expression of higher cellular adhesion molecules.[@bib11]^,^[@bib14]^--^[@bib24] It has been shown that, upon infection, CMV replicates in corneal endothelial cells in vitro,[@bib25] and endothelial cells infected with CMV rapidly induce apoptosis to inhibit viral growth.[@bib26] Rho--Rho kinase (ROCK) signaling occurs downstream in TNF-α-mediated pathophysiological disorders, resulting in endothelial damage, apoptosis, and/or higher cellular permeability[@bib27]^--^[@bib29]; however, few studies have focused on the involvement of TNF-α--Rho--ROCK signaling in damage to corneal endothelial cells. Therefore, in the present study, we sought to determine if aqueous TNF-α is involved in the pathophysiology of corneal endothelial cell loss in CMV-positive PSS patients. We then investigated whether CMV-induced corneal endothelial cell apoptosis could be attenuated by ROCK inhibitors. Our results showed that the TNF-α-induced activation of Rho--ROCK signaling was a crucial event not only in the loss of barrier integrity and disruption of the cytoskeleton but also in the loss of corneal endothelial cells.

Patients and Methods {#sec2}
====================

Patients and AH Samples {#sec2-1}
-----------------------

AH samples were obtained March 2014 to July 2018 at the University of Tokyo Hospital from patients who underwent cataract surgery and were confirmed negative for CMV DNA in the aqueous humor by PCR testing, as well as from patients with clinical signs of CMV AU who underwent PCR testing and were confirmed positive for CMV DNA in the aqueous humor. This prospective observational study was approved by the Institutional Review Board of the University of Tokyo and was registered with the University Hospital Medical Information Network Clinical Trials Registry of Japan (ID: UMIN000027137). All procedures conformed to the tenets of the Declaration of Helsinki, and written informed consent was obtained from all patients.

The inflammation was analyzed according to the criteria of the Standardization of Uveitis Nomenclature (SUN) working group, including in terms of the anatomical location, onset, duration, course, and activity.[@bib30] The diagnostic criteria for PSS were as follows: recurrent elevated IOP (\>21 mm Hg) and mild (SUN grade of 1) intermittent anterior chamber inflammation with fine-to-medium-sized keratic precipitates and unilateral eye involvement. Exclusion criteria included the presence of other types of ocular diseases; possible systemic, genetic, or infectious origin of the inflammation; or a previous history of intraocular surgery other than small-incision cataract surgery without complications. All patients were negative for tuberculosis, sarcoidosis, syphilis and herpes simplex virus, varicella-zoster virus, rubella virus, and toxoplasmosis genomic DNA in the aqueous samples, as assessed by PCR and immunocompetence. The IOP was determined using a Goldmann tonometer. In all patients, the anterior eye segment and optic disc were examined by glaucoma or uveitis specialists using a slit-lamp biomicroscope and dilated fundoscopy to diagnose glaucoma.

AH Collection {#sec2-2}
-------------

AH samples were collected as described previously.[@bib31] Briefly, in eyes with PSS, AH was collected in the outpatient clinic before commencement of treatment. Under topical anesthesia, approximately 70 to 100 µL of AH was obtained using a 30-gauge syringe, collected in a ProteoSave SS 1.5-mL Slimtube (Sumitomo Bakelite, Tokyo, Japan), and then registered and stored at --80°C until processing. For cataract controls, the AH was collected at the beginning of cataract surgery, after paracentesis was performed.

Measurement of Cytokines in the AH {#sec2-3}
----------------------------------

The cytokine levels in the AH were measured using the Bio-Plex Pro Human Cytokine 27-Plex Immunoassay (Bio-Rad Laboratories, Hercules, CA, USA), following the manufacturer\'s protocols.

Culturing of Human Corneal Endothelial Cells {#sec2-4}
--------------------------------------------

Primary culturing of human corneal endothelial cells (hCECs) was performed as described previously.[@bib32] The cells were cultured at 37°C in 5% CO~2~, and cells from passages 57 to 60 were used for the experiments.

Virus Infection {#sec2-5}
---------------

We used an endotheliotropic human cytomegalovirus (HCMV) strain AD169/rev for hCEC infection. AD169/rev is a virus mutant strain modified from AD169 so that it can easily infect endothelial cells, including ARPE-19, which can be used for a CMV cell line or replication of the virus.[@bib33] To obtain AD 169/rev, the culture fluid from ARPE-19 cells transfected with AD169/rev clone at a multiplicity of infection (MOI) of 0.4 was collected after culturing for 5 days. The culture supernatants were harvested, followed by centrifugation for 10 minutes at 3000 rpm at room temperature to prepare cell-free CMV medium. The harvested medium was used after one cycle of freezing and thawing. After reaching confluence, the hCECs were incubated with the cell-free CMV medium for 2 hours at 37°C in 5% CO~2~ with a MOI of 1. After exposure, the cell-free CMV medium was removed, and the infected cells were washed twice with 1× PBS, followed by incubation in growth medium. Infected hCECs were then grown in the growth medium. To confirm whether hCECs were infected, the cells were stained with Mouse Anti-Cytomegalovirus Monoclonal Antibody (MAB810R), clone 8B1.2 (Sigma-Aldrich, St. Louis, MO, USA), which reacts with an immediate-early (IE) non-structural antigen of 68--72 kDa, to check the expression of IE antigen. The IE antigen was detected 1 day after exposure to cell-free CMV medium ([Supplementary Figure S1](#iovs-61-10-5_s001){ref-type="supplementary-material"}).

Immunocytochemistry {#sec2-6}
-------------------

Immunocytochemistry (ICC) was performed as previously described.[@bib34] The cells were grown in chamber slides. The hCECs were fixed in ice-cold 4% paraformaldehyde for 15 minutes 1 day after infection and then permeabilized with 0.3% Triton X-100 (Sigma-Aldrich) for 5 minutes and blocked in 3% BSA for 30 minutes. The primary antibodies were anti-CMV, clone 8B1.2 (1:2000; Sigma-Aldrich); anti-ZO-1 (1:100; Abcam, Cambridge, UK); anti-TNF-α (1:500; Abcam); and anti-nuclear factor kappa B (NF-κB) (1:100; Sigma-Aldrich). Alexa Fluor 488 and 594 secondary antibodies (1:1000) were purchased from Thermo Fisher Scientific (Waltham, MA, USA). We further determined if changes induced by CMV infection were suppressed by ROCK inhibitors (Y27632, K115), because the Rho--ROCK pathway is a common downstream component of TNF-α signaling.

Quantitative PCR {#sec2-7}
----------------

The cells were lysed using TRI Reagent (Molecular Research Center, Inc., Cincinnati, OH, USA), and mRNA was isolated using chloroform and isopropyl alcohol. The mRNA was treated with a PrimeScript RT Reagent Kit (Takara Bio, Shiga, Japan) to synthesize cDNA. mRNA was quantified using quantitative PCR (qPCR) with SYBR Premix Ex Taq II (Tli RNase H Plus) (Takara Bio) and the Thermal Cycler Dice Real Time System II (Takara Bio) using the ΔΔCt method. For qPCR, primer sequences were taken from previously published sequences, and the primers were purchased from Hokkaido System Science (Hokkaido, Japan). The sequences of the PCR primers were as follows: glyceraldehyde 3-phosphate dehydrogenase (GAPDH), forward, 5′-GAGTCAACGGATTTGGTCGT-3′, and reverse, 5′-TTGATTTTGGAGGGATCTCG-3′; IL-10, forward, 5'- GCCTAACATGCTTCGAGATC, and reverse, 5'- TGATGTCTGGGTCTTGGTTC; and TNF-α, forward, 5'- CCCGAGTGACAAGCCTGTAG, and reverse, 5'- GATGGCAGAGAGGAGGTTGAC. The data were normalized relative to GAPDH.

Cell Fractionation {#sec2-8}
------------------

CMV-infected hCECs with or without ROCK inhibitors (Y27632, K115) or JSH-23 (inhibitor of NF-κB transcriptional activity) were fractionated using the Abcam Cell Fractionation Kit (Standard) following the manufacturer\'s protocol.

Western Blotting {#sec2-9}
----------------

One day after CMV infection with or without Y27632 or K115, the cells were collected in RIPA buffer (Thermo Fisher Scientific) containing protease inhibitors (Roche Diagnostics, Basel, Switzerland). They were then sonicated and centrifuged. Western blotting (WB) was performed as described previously.[@bib34] The primary antibodies were as follows: anti-TNF-α (1:500; Abcam), anti-NF-κB (1:100; Sigma-Aldrich), anti-IL-10 (1:500; Abcam), Phospho-IκBα (Ser32/36) (5A5) antibody (1:1000, Cell Signaling Technology), and anti-GAPDH (1:1000; Wako Pure Chemical Industries, Osaka, Japan). Horseradish peroxidase (HRP)-conjugated secondary antibody (1:2000) was purchased from Thermo Fisher Scientific. The bands were quantified using ImageJ 1.49 software (National Institutes of Health, Bethesda, MD, USA).

Evaluation of Apoptosis and Cell Death {#sec2-10}
--------------------------------------

After incubation, we used the Vybrant Apoptosis Assay Kit (Thermo Fisher Scientific) to quantify apoptotic hCECs infected with CMV. After CMV infection, the hCECs were stained using Alexa Fluor 488-conjugated annexin V binding combined with propidium iodide labeling. Apoptotic hCECs were stained as annexin V(+)/propidium iodide(--), and necrotic cells were stained as annexin V(+)/propidium iodide(+). Undamaged hCECs remained negative for both stains.[@bib35]^,^[@bib36] At the end of the double-staining procedure, Hoechst 33342 was added to the culture medium to a final concentration of 8 mM. The cells were counted in at least seven random fields of each well at 200× magnification using a fluorescence microscope (BZ-9000; Keyence, Tokyo, Japan). The percentages of apoptotic hCECs and necrotic hCECs were quantified by determining the ratio of annexin V(+)/propidium iodide(--) cells and annexin V(+)/propidium iodide(+) cells to Hoechst 33342(+) retinal ganglion cells, respectively. The cells were counted in a masked manner.

RhoA Activation Assay {#sec2-11}
---------------------

RhoA is a Rho GTPase, a family within the Ras superfamily of monomeric small guanosine triphosphate (GTP)-binding proteins that act as molecular switches that cycle between a GTP-bound active and a GDP-bound inactive conformation. We also performed RhoA activation assays to confirm whether CMV infection in hCECs can induce RhoA. Thirty minutes after CMV infection, RhoA activation was examined using a pull-down assay (RhoA Activation Assay Biochem Kit; Cytoskeleton, Inc., Denver, CO, USA), according to the manufacturer\'s instructions. HRP-conjugated secondary antibody (1:1000) was purchased from Thermo Fisher Scientific. Protein bands were detected using an ImageQuant LAS 4000 mini biomolecular imager (GE Healthcare, Chicago, IL, USA). The bands were quantified using Adobe Photoshop (Adobe Inc., San Jose, CA, USA).

Measurement of Monolayer Cell Permeability and Monolayer Transendothelial Electrical Resistance in the hCECs {#sec2-12}
------------------------------------------------------------------------------------------------------------

To measure the monolayer cell permeability, hCECs were grown on Corning Transwell polycarbonate membrane inserts (0.4-µm pore size and 12-mm diameter; Sigma-Aldrich) on 12-well culture plates (BD Falcon, Franklin Lakes, NJ, USA) at 37°C in 5% CO~2~ until confluent as previously described.[@bib37] The volume of the applied medium was 0.5 mL on the apical side (inside of the membrane inserts) and 1.5 mL on the basal side (outside of the membrane inserts). Two weeks after seeding, hCEC-cell monolayers were exposed to the cell-free CMV medium for 2 hours and washed with PBS(--) twice, and we further determined if changes induced by CMV infection were suppressed by ROCK inhibitors (Y27632, K115) or JSH-23. A 4-kDa FITC--dextran dye (Sigma-Aldrich) was simultaneously applied together with those inhibitors at 50 µM to the basal compartment of the wells. Also, transendothelial electrical resistance (TEER) was recorded using Millicell ERS (Sigma-Aldrich) according to the manufacturer\'s instructions. The medium was collected from the apical side for fluorescence measurements at 1, 3, 6, and 12 hours after adding the dye, and the same volume of fresh culture medium was replaced. The concentration of FITC--dextran in the collected medium was measured using a multimode plate reader (MTP-800AFC Multi-Detection Microplate Reader; Corona Electric, Ibaragi, Japan), with an excitation wavelength of 490 nm and an emission wavelength of 530 nm. Fluorescence intensity of the normal medium was measured as the background concentration in each experiment. Also, time-dependent changes of TEER were compared as percent change of reduction from baseline values. Each experiment was repeated at least three times.

Statistical Analysis {#sec2-13}
--------------------

The data were statistically analyzed using the EZR program (Saitama Medical Center, Hidaka, Japan).[@bib38] The results are expressed as mean ± standard deviation (SD). The *t*-test and χ^2^ or Fisher\'s exact test were used for comparing two variables, and the Steel--Dwass test was used for analyzing multiple variables. Differences among groups were analyzed by one-way ANOVA and Tukey\'s test as a post hoc test. A value of *P* \< 0.05 was considered statistically significant.

Results {#sec3}
=======

Demographic Data of the Study Population {#sec3-1}
----------------------------------------

[Table 1](#tbl1){ref-type="table"} lists the demographic data of the study population. There were 20 subjects in the control group (eyes without any ocular complications) and 19 CMV-positive PSS patients.

###### 

Demographic Characteristics of the Study Population

  Variables                                            Control                       CMV+/PSS                     *P* [^\*^](#tb1fn1){ref-type="table-fn"}
  ---------------------------------------------------- ----------------------------- ---------------------------- ---------------------------------------------
  Patients (*n*)                                       20                            19                           ---
  Eyes (*n*)                                           20                            19                           ---
  Gender, male:female (*n*)                            8:12                          15:4                         \<0.005[^†^](#tb1fn2){ref-type="table-fn"}
  Age (y), mean ± SD (range)                           73.5 ± 3.8 (58--87)           62.7 ± 7.4 (39--86)          \<0.005[^‡^](#tb1fn3){ref-type="table-fn"}
  IOP (mm Hg), mean ± SD (range)                       13.5 ± 0.7 (12--16)           19.6 ± 4.0 (8--34)           \<0.001[^‡^](#tb1fn3){ref-type="table-fn"}
  Corneal endothelial cells (*n*), mean ± SD (range)   2644.9 ± 123.5 (2321--3251)   2027.1 ± 355.5 (388--2778)   \<0.001[^‡^](#tb1fn3){ref-type="table-fn"}
  Glaucoma eye drops (*n*), mean ± SD (range)          ---                           0.8 ± 2.1 (0--4)             ---
  Aqueous TNF-α level (pg/mL), mean ± SD (range)       4.0 ± 9.1 (0-34.71)           45.3 ± 28.8 (3.4-79.5)       \<0.0001[^‡^](#tb1fn3){ref-type="table-fn"}

All *P* represent a statistically significant difference between control and CMV+/PSS (Steel--Dwass test).

Fisher\'s exact test.

Mann--Whitney *U*-test.

The ratio of males to females was 8:12 in the control group and 15:4 in the CMV+/PSS group ([Table 1](#tbl1){ref-type="table"}). The IOP was significantly higher in the CMV+/PSS group compared to the control group ([Table 1](#tbl1){ref-type="table"}). The number of corneal endothelial cells was significantly lower in the CMV+/PSS group compared to the control group ([Table 1](#tbl1){ref-type="table"}). The aqueous and overall levels of TNF-α were significantly higher in the CMV+/PSS group compared to the control group (*P* \< 0.001; [Table 1](#tbl1){ref-type="table"}).

The IL-8, IL-10, eotaxin, monocyte chemoattractant protein-1 (MCP-1), IL-4, and RANTES (regulated upon activation, normal T-cell expressed and secreted) levels were significantly higher in the CMV+/PSS group compared to the control group (*P* \< 0.01) ([Table 2](#tbl2){ref-type="table"}).

###### 

Comparing the Concentrations (pg/mL) of Each Cytokine

            Mean ± SD (range)                                                      
  --------- ---------------------------------- ----------------------------------- ---------
  IL-1β     0.05 ± 0.02 (0.02--0.09)           0.23 ± 0.33 (0.22--0.99)            NS
  IL-1Ra    93.73 ± 7.81 (6.88--259.4)         193.09 ± 154.54 (43.86--504.39)     NS
  IL-8      13.87 ± 13.08 (4.14--61.22)        49.09 ± 29.34 (18.52--116.21)       \<0.001
  IL-10     0.45 ± 0.37 (0.04--1.19)           10.50 ± 11.86 (0.40--38.15)         \<0.001
  MCP-1     287.96 ± 124.82 (164.26--647.78)   791.25 ± 1122.7 (227.22--3917.48)   \<0.05
  Eotaxin   4.95 ± 1.74 (1.95--8.10)           12.37 ± 35.64 (2.52--35.64)         \<0.01
  FGF       2.00 ± 2.58 (0.07--11.70)          5.06 ± 5.34 (0.07--15.88)           NS
  IFN-γ     6.58 ± 4.94 (0.67--20.84)          30.04 ± 50.27 (2.21--161.17)        NS
  IL-4      0.12 ± 0.06 (0.08--0.22)           0.72 ± 0.67 (0.08--1.60)            \<0.05
  IL-6      12.90 ± 18.30 (0.79--74.87)        11.00 ± 13.89 (0.79--35.85)         NS
  IL-7      4.33 ± 3.41 (0.78--14.94)          4.16 ± 2.62 (0.78--7.79)            NS
  IL-9      1.46 ± 1.25 (0.31--4.02)           4.10 ± 4.72 (0.76--7.44)            NS
  IL-12     0.57 ± 0.67 (0.08--3.22)           0.39 ± 0.28 (0.08--0.96)            NS
  IL-13     1.42 ± 0.21 (1.27--1.57)           1.85 ± 1.90 (0.5--3.19)             NS
  IL-17     1.76 ± 3.49 (0.06--11.05)          5.56 ± 8.35 (0.06--24.93)           NS
  RANTES    5.44 ± 0.92 (3.02--6.84)           24.14 ± 41.21 (2.65--139.36)        \<0.001

^\*^Mann--Whitney *U*-test.

The number of corneal endothelial cells was negatively correlated with the aqueous TNF-α level (Spearman\'s rank correlation coefficient: --0.391, *P* \< 0.05) ([Table 1](#tbl1){ref-type="table"}, [Fig. 1](#fig1){ref-type="fig"}A), and the aqueous level of IL-10 was negatively correlated with the number of corneal endothelial cells ([Fig. 1](#fig1){ref-type="fig"}C). However, there was no significant correlation between the number of corneal endothelial cells and the levels of IL-8, eotaxin, MCP-1, IL-4, or RANTES ([Figs. 1](#fig1){ref-type="fig"}B, [1](#fig1){ref-type="fig"}D, [1](#fig1){ref-type="fig"}E, [1](#fig1){ref-type="fig"}F, and [1](#fig1){ref-type="fig"}G, respectively).

![Relationship between aqueous cytokine level and the number of corneal endothelial cells in CMV-positive PSS patients, showing aqueous cytokine levels in PSS patients as measured by a multiplex assay. (**A**, **C**) The aqueous TNF-α and IL-10 levels were negatively correlated with the number of corneal endothelial cells (*P* \< 0.05). (**B,** **D--G**) The aqueous IL-10, eotaxin, MCP-1, IL-4, and RANTES levels had no relationship with the number of corneal endothelial cells.](iovs-61-10-5-f001){#fig1}

Assessment by WB of IL-10 Expression in CMV-Infected hCECs {#sec3-2}
----------------------------------------------------------

[Figure 2](#fig2){ref-type="fig"}A shows the WB data (*n* = 3), which indicated that the expression of IL-10 was slightly upregulated with CMV infection. The quantitative analysis showed that the expression of IL-10 was significantly upregulated at 1 day after infection ([Fig. 2](#fig2){ref-type="fig"}B).

![(**A**, **B**) Western blotting of IL-10 in CMV-infected hCECs. The bands for WB are shown in **A**, and **B** shows the relative expression of IL-10 (*n* = 3). The results are expressed relative to the loading control of GAPDH. IL-10 was upregulated in hCECs with CMV infection. ^\*^*P* \< 0.05. (**C**, **D**) RhoA activation assay of in CMV-infected hCECs. The bands for WB are shown in **C**, and the expression of active RhoA (*n* = 3) relative to total RhoA is shown in **D**. Active RhoA was upregulated in hCECs with CMV infection. ^\*^*P* \< 0.05. (**E**, **F**) qPCR quantification of IL-10 and TNF-α in CMV-infected hCECs. The relative mRNA expression of IL-10 (**E**) and TNF-α (**F**) was significantly higher in CMV-infected cells compared to the control. When the ROCK inhibitors (Y27632, K115) or JSH-23 were applied after CMV infection, the expression of TNF-α was significantly downregulated. RT-qPCR with GAPDH primers was performed to serve as an internal control for input DNA. Data are the averages of four independent DNA samples from the infected cells. Values are the mean ± SE. ^\*^*P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.01.](iovs-61-10-5-f002){#fig2}

Activated RhoA {#sec3-3}
--------------

[Figure 2](#fig2){ref-type="fig"}C shows the data from the RhoA activation assay (*n* = 3), indicating that the expression of active RhoA was upregulated after CMV infection. The quantitative analysis showed that the expression of active RhoA was significantly upregulated at 1 day after infection ([Fig. 2](#fig2){ref-type="fig"}D).

CMV-Induced mRNA Expression of IL-10 and TNF-α {#sec3-4}
----------------------------------------------

We analyzed the mRNA expression levels of IL-10 and TNF-α in CMV-infected hCECs using qRT-PCR ([Figs. 2](#fig2){ref-type="fig"}E, [2](#fig2){ref-type="fig"}F). Basal levels of IL-10 and TNF-α were detectable in CMV-infected hCECs, and, compared with the control, CMV infection significantly increased the expression of IL-10 and TNF-α (*P* \< 0.001) ([Figs. 2](#fig2){ref-type="fig"}E, [2](#fig2){ref-type="fig"}F). When the ROCK inhibitors (Y27632, K115) or JSH-23 were applied after CMV infection, the expression of TNF-α was significantly downregulated (*P* \< 0.01 for Y27632; *P* \< 0.001 for K115 and JSH-23) ([Fig. 2](#fig2){ref-type="fig"}F).

Assessment by ICC and WB of TNF-α, NF-κB, and Phospho-IκBα Expression in CMV-Infected hCECs {#sec3-5}
-------------------------------------------------------------------------------------------

First, ICC and WB were used to assess the expression levels of TNF-α, NF-κB, and Phospho-IκBα after CMV infection. [Figure 3](#fig3){ref-type="fig"} shows the immunocytochemistry results, which indicate that the expression levels of TNF-α and NF-κB were upregulated after CMV infection but attenuated after treatment with ROCK inhibitors ([Fig. 3](#fig3){ref-type="fig"}). [Figure 4](#fig4){ref-type="fig"} shows the WB results (*n* = 3), which also indicate that the expression levels of TNF-α ([Fig. 4](#fig4){ref-type="fig"}A), NF-κB ([Fig. 4](#fig4){ref-type="fig"}C) and Phospho-IκBα ([Fig. 4](#fig4){ref-type="fig"}E) were upregulated at 1 day after infection but attenuated after treatment with ROCK inhibitors. Also, expression of Phospho-IκBα was downregulated with JSH-23. The quantitative analysis showed that the expression levels of TNF-α, NF-κB, and Phospho-IκBα were significantly upregulated at 1 day after infection ([Figs. 4](#fig4){ref-type="fig"}B, [4](#fig4){ref-type="fig"}D, [4](#fig4){ref-type="fig"}F).

![ICC of TNF-α and NF-κB in CMV-infected hCECs. The *left panels* show cells that were stained with 4′,6-diamidino-2-phenylindole (DAPI). The middle panels show cells stained for TNF-α (**A**) or NF-κB (**B**). The *right panels* show merged images. The expression data for mock infection are shown in the first row; those for CMV infection, in the second row; those for CMV infection under Y27632, in the third row; and those for CMV infection under K115, in the fourth row. Both TNF-α and NF-κB expression levels were higher after infection but were attenuated in the presence of ROCK inhibitors. *Scale bar*: 200 µm.](iovs-61-10-5-f003){#fig3}

![WB of TNF-α, NF-κB, and Phospho-IκBα in CMV-infected hCECs showing the expression levels of TNF-α (**A**), NF-κB (**C**), and Phospho-IκBα (**E**). In the *left row*, the bands for WB are shown; in the *right row*, the expression levels of TNF-α, NF-κB, and Phospho-IκBα (*n* = 3) and the results expressed relative to the loading control (GAPDH) are shown. (**B**, **D**, **F**) These components were upregulated in hCECs with CMV infection and downregulated in the presence of ROCK inhibitors. Also, the expression of and Phospho-IκBα was downregulated with JSH-23. ^\*^*P* \< 0.05; ^\*\*^*P* \< 0.01; ^\*\*\*^*P* \< 0.001.](iovs-61-10-5-f004){#fig4}

Effect of CMV Infection on Apoptosis and Necrosis of hCEC {#sec3-6}
---------------------------------------------------------

[Figure 5](#fig5){ref-type="fig"} shows representative fluorescence microscopy images of Hoechst 33342 and annexin V/propidium iodide staining at 1 day after infection. The green staining denotes annexin V-positive cells ([Fig. 5](#fig5){ref-type="fig"}A), the red staining denotes propidium iodide-positive cells ([Fig. 5](#fig5){ref-type="fig"}B), and the blue staining denotes Hoechst 33342-positive cells ([Fig. 5](#fig5){ref-type="fig"}C). [Figure 5](#fig5){ref-type="fig"}D is a merged image showing annexin V(+)/propidium iodide(--) apoptotic cells (white arrow) and annexin V(+)/propidium iodide(+) necrotic cells (yellow arrow). Compared to the normal controls, CMV infection significantly increased apoptosis (2.4 ± 1.9% vs. 6.4 ± 2.0%; *P* \< 0.001, Wilcoxon rank-sum test) ([Fig. 5](#fig5){ref-type="fig"}E) but not necrosis (5.0 ± 1.8% vs. 6.0 ± 2.6 %; *P* = 0.81, Wilcoxon rank-sum test) ([Fig. 5](#fig5){ref-type="fig"}F). The percentages of apoptotic and necrotic hCECs in the ROCK inhibitor group were 3.8 ± 0.8% and 7.3 ± 1.2%, respectively, for the Y27632 group (*n* = 6) and 2.6 ± 1.2% and 4.1 ± 1.9%, respectively, for the K115 group (*n* = 6). Treatment with ROCK inhibitors significantly reduced apoptosis of hCEC.

![Representative fluorescence microscopy images of Hoechst 33342 and annexin V/propidium iodide staining at 24 hours after CMV infection to detect apoptotic and necrotic hCECs post-CMV infection with or without ROCK inhibitors. (**A**) *Green staining* is annexin V-positive cells. (**B**) *Red staining* is propidium iodide-positive staining cells. (**C**) *Blue staining* is Hoechst 33342-positive staining cells. (**D**) Merged image showing annexin V(+)/propidium iodide(--) apoptotic cells (*white arrow*) and annexin V(+)/propidium iodide(+) necrotic cells (*yellow arrow*). (**E**) Ratio of apoptotic cells. CMV infection increased the percentage of apoptotic cells, and ROCK inhibitors significantly decreased the CMV infection-induced expression of apoptotic cells. (**F**) The expression level of necrotic cells did not differ among groups. Each value represents the mean ± SD (*n* = 6). ^\*^*P* \< 0.05; ^\*\*^*P* \< 0.01; ^\*\*\*^*P* \< 0.001.](iovs-61-10-5-f005){#fig5}

Cell--Cell Contact and Cell Permeability in hCECs Assessed by FITC--Dextran Flux and TEER {#sec3-7}
-----------------------------------------------------------------------------------------

In an attempt to confirm the effect of ROCK inhibitors to restore the decreased cell--cell adhesion and barrier function in CMV-infected hCECs, we performed permeability assays using a flux of FITC--dextran and measurement of TEER in hCECs. CMV infection significantly increased the concentration of FITC--dextran in the apical side of CEC (corneal endothelial cells) cells at 1 and 3 hour after FITC--dextran exposure (*P* \< 0.001 for 1 hour, *P* \< 0.05 for 3 hours) ([Fig. 6](#fig6){ref-type="fig"}A). Additionally, when ROCK inhibitors (Y27632 and K115) were applied together, those inhibitors significantly attenuated the changes induced by CMV infection 1 hour after FITC--dextran exposure (*P* \< 0.01) ([Fig. 6](#fig6){ref-type="fig"}A). Also, Y27632 significantly attenuated the changes induced by CMV infection at 3 hours after FITC--dextran exposure; K115 failed to show significance (*P* = 0.096). There was no significant difference at 6 and 12 hours after FITC--dextran exposure. Although JSH-23 failed to show significant differences among mock infections at any time points, it did show a tendency to suppress the increased TEER at 1 hour and 3 hours (*P* = 0.062 and *P* = 0.066, respectively).

![Measurement of monolayer cell permeability in CMV-infected hCECs with or without inhibitors. (**A**) Changes in the hCEC monolayer permeability using 4-kDa FITC--dextran are shown. hCECs were infected with CMV, and concentrations were measured at 1, 3, 6, and 12 hours after exposure of the FITC--dextran. Mean values from four separate filters are presented. hCEC monolayer permeability was significantly increased after CMV infection at 1 hour and 3 hours. hCEC monolayer permeability decreased in the presence of the ROCK inhibitors (Y27632, 100 µM; K115, 100 µM). Although JSH-23 (10 µM) failed to show a significant difference, it did show a tendency to suppress the increased TEER at 1 hour and 3 hours (*P* = 0.062 and *P* = 0.066, respectively). \**P* \< 0.05, ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001. (**B**) Effect of CMV infection on TEER in hCEC monolayer. hCECs were infected with CMV. TEER was measured at 1, 3, 6, and 12 hours from infection. Data are shown as mean values ± SE from four separate filters. TEER in the hCEC monolayer was significantly reduced after CMV infection at 3, 6, and 12 hours. The decrease in TEER was attenuated with the presence of the ROCK inhibitors (Y27632, 100 µM; K115, 100 µM) or JSH-23 (10 µM). ^\*\*^*P* \< 0.01, ^\*\*\*^*P* \< 0.001.](iovs-61-10-5-f006){#fig6}

[Figure 6](#fig6){ref-type="fig"}B shows the results of the TEER on CMV infection and whether or not those changes were attenuated with ROCK inhibitors (Y27632, K115) or JSH-23. CMV infection showed significant decrease in TEER at 3, 6, and 12 hours after CMV infection, and the change in TEER was significantly restored when ROCK inhibitors (Y27632, K115) or JSH-23 were applied. These observations suggested that simultaneous administration of ROCK inhibitors (Y27632, K115) or JSH-23 inhibited the CMV infection-induced a decrease in the barrier functions of the hCEC monolayer.

Barrier Integrity and Cytoskeletal Changes in hCEC as Assessed by ICC {#sec3-8}
---------------------------------------------------------------------

The expression of zonula occludens-1 (ZO-1) and F-actin was decreased in CMV-infected hCECs compared to the control group ([Figs. 7](#fig7){ref-type="fig"}A, [7](#fig7){ref-type="fig"}B), and these CMV infection-induced changes were significantly attenuated in the presence of ROCK inhibitors (Y27632, K115).

![ICC of ZO-1 and F-actin in hCECs infected with CMV. (**A**) The *left panels* show cells that were stained with DAPI, the *middle panels* show cells stained for ZO-1, and the *right panels* show merged images. The expression data for mock infection are shown in the first row; those for CMV infection, in the second row; those for CMV infection in the presence of Y27632, in the third row; and those for CMV infection in the presence of K115, in the fourth row. Cell--cell contact was impaired after CMV infection, but this change was attenuated by ROCK inhibitors. *Scale bar*: 200 µm. (**B**) The *left panels* show cells that were stained with DAPI, the *middle panels* show cells stained for F-actin, and the *right panels* show merged images. The expression data for mock infection are shown in the first row; those for CMV infection, in the second row; those for CMV infection under Y27632, in the third row; and those for CMV infection in the presence of K115, in the fourth row. Cytoskeletal formation was impaired after CMV infection, but this change was attenuated by ROCK inhibitors. *Scale bar*: 200 µm.](iovs-61-10-5-f007){#fig7}

Discussion {#sec4}
==========

In this study, we found that the concentration of TNF-α in aqueous samples of CMV-positive PSS patients was significantly higher compared to healthy control patients without ocular inflammatory conditions, and the aqueous TNF-α negatively correlated with the number of corneal endothelial cells. Several studies have reported changes in the aqueous cytokine profiles of different clinical entities of uveitis, including infectious uveitis,[@bib39] Beçhet\'s disease, Vogt--Koyanagi--Harada disease,[@bib40]^,^[@bib41] Fuchs' heterochromic cyclitis (FHC), and other types of clinically idiopathic uveitis.[@bib42]^--^[@bib45] Increased levels of IL-6, MCP-1, and IL-8 are commonly observed in ocular inflammatory diseases, and similar changes in these cytokines have also been reported in PSS patients.[@bib7] It has been reported that PSS patients show a stronger and more active ocular inflammatory response compared to healthy controls and FHC patients, with higher concentrations of IL-1RA, IL-8, and IL-10.[@bib7]^,^[@bib10] In the present study, we also found that the IL-8, IL-10, eotaxin, MCP-1, IL-4, and RANTES levels were significantly higher in the CMV+/PSS group compared to the control group (*P* \< 0.01) ([Table 2](#tbl2){ref-type="table"}), and the elevations in levels of MCP-1, IL-8, and IL-10 were consistent with previous reports. Among the upregulated cytokines, there was no significant correlation between the number of corneal endothelial cells and levels of IL-8, eotaxin, MCP-1, IL-4, or RANTES ([Figs. 1](#fig1){ref-type="fig"}B, [1](#fig1){ref-type="fig"}D, [1](#fig1){ref-type="fig"}E, [1](#fig1){ref-type="fig"}F, and [1](#fig1){ref-type="fig"}G, respectively), but TNF-α and IL-10 ([Figs. 1](#fig1){ref-type="fig"}A and [1](#fig1){ref-type="fig"}C, respectively) showed significant correlations with decreased corneal endothelial cells.

However, there were some discrepancies among previous reports regarding the aqueous levels of TNF-α in PSS patients. Li et al.^7^ evaluated the differences in aqueous cytokine levels between PSS patients with and without CMV, but they failed to detect aqueous TNF-α in PSS patients, regardless of the presence of CMV viral DNA. However, a recent study by Pohlmann et al.[@bib10] reported that the aqueous TNF-α level was significantly higher compared to the control. In the present study, we found significantly higher levels of TNF-α in CMV+/PSS patients compared to controls, which is consistent with the latter report.

Because we found that TNF-α and IL-10 levels were upregulated in CMV+/PSS patients and showed significant correlations with the decrease in corneal endothelial cells ([Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"} and [Figs. 1](#fig1){ref-type="fig"}A and [1](#fig1){ref-type="fig"}C, respectively), we conducted in vitro studies to confirm whether the TNF-α and IL-10 levels were induced by CMV infection in hCECs. First, we used ICC to confirm CMV infection in hCECs ([Supplementary Figure S1](#iovs-61-10-5_s001){ref-type="supplementary-material"}) and found that infection was established 1 day after infection when the hCECs were exposed to CMV at a MOI of 0.1. [Figures 2](#fig2){ref-type="fig"}F, [3](#fig3){ref-type="fig"}A, and [4](#fig4){ref-type="fig"}A show that CMV infection in hCECs was significantly induced by TNF-α expression, which was confirmed by rPCR, ICC, and WB. CMV infection also slightly induced the expression of IL-10 ([Figs. 2](#fig2){ref-type="fig"}A, [2](#fig2){ref-type="fig"}B, [2](#fig2){ref-type="fig"}E). CMV+/PSS is known to cause chronic uveitis with a higher recurrence rate; in such incidents, due to the chronic inflammatory state, antiinflammatory cytokines including IL-10 may be induced to antagonize the uveitis. Barton et al.[@bib46]^,^[@bib47] reported that in animal models of experimental autoimmune uveitis, the T cells found in the early stage of the disease were mainly CD4+T cells secreting Th1-type cytokines (IFN-γ) and that in the latter stage a shift was taking place toward the Th2 type cytokines (IL-10). Therefore, we hypothesized that chronic inflammatory state in CMV+/PSS may have induced upregulation of IL-10 in the aqueous humor in the present study. [Figures 2](#fig2){ref-type="fig"}C and [2](#fig2){ref-type="fig"}D show that using the Rho pull-down assay, CMV-infected hCECs exhibited significant upregulation of active RhoA compared to mock infection. In addition, [Figure 3](#fig3){ref-type="fig"}B shows that the translocation of NF-κB to the nucleus was accelerated after CMV infection, suggesting that TNF-α-related cellular responses, including prolonged inflammation or apoptosis, may be promoted through the upregulation of NF-κB and RhoA.

TNF-α has been implicated in endothelial dysfunction and apoptosis during corneal allograft rejection and AU.[@bib11]^,^[@bib48]^,^[@bib49] Past studies have reported a correlation between TNF-α and ROCK; TNF-α induced activated Rho, whereas ROCK promoted translocation of NF-κB to the nucleus to accelerate the production of TNF-α.[@bib50]^,^[@bib51] Based on these results, we speculated that higher expression of TNF-α induced CMV-infected hCECs and active RhoA, resulting in translocation of NF-κB to the nucleus to induce apoptosis. Also, NF-κB translocation to the nucleus may accelerate the production of TNF-α to maintain RhoA in an activated state.

In the present study, therefore, we focused on TNF-α--Rho--ROCK signaling induced by CMV infection in hCECs, and further characterized the role of TNF-α in corneal endothelial cell death to determine if corneal endothelial cell death was suppressed in the presence of ROCK inhibitors. It has been suggested that Rho--ROCK signaling not only acts on the downstream cascade of TNF-α but also works as a generator of TNF-α. In corneal endothelial cells, it has been reported that overexpression of ROCK1 may trigger lipopolysaccharide-induced production of TNF-α and its downstream apoptosis, which could be attenuated with ROCK inhibitors.[@bib51] Yang et al.[@bib50] reported a preservative effect of ROCK inhibitors on the apoptosis of microvascular endothelial cells via inhibition of the nuclear translocation of NF-κB and consequent suppression of the generation of TNF-α. We therefore hypothesize that ROCK inhibitors may modulate the CMV-infection-induced generation of TNF-α. As shown in [Figures 2](#fig2){ref-type="fig"}F, [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}, CMV-infection-induced upregulation of TNF-α, NF-κB, and Phospho-IκBα was significantly downregulated by ROCK inhibitors (Y27632, K115). Also, the expression of Phospho-IκBα was downregulated under JSH-23. These data suggest that CMV induces the phosphorylation of IκB, which leads to the translocation of NF-κB into the nucleus to induce apoptosis.

In the next step, we further investigated whether corneal endothelial cells underwent apoptosis post-CMV infection, which would be attenuated by ROCK inhibitors.[@bib13]^,^[@bib20]^,^[@bib52]^,^[@bib53] We conducted an apoptosis activity assay to confirm whether CMV induced apoptosis in hCECs and whether this was attenuated by ROCK inhibitors. [Figure 5](#fig5){ref-type="fig"} shows that the apoptosis rate was significantly elevated in hCECs during post-CMV infection ([Fig. 5](#fig5){ref-type="fig"}E), and these changes were significantly decreased by treatment with ROCK inhibitors. Past reports have shown that endothelial cells infected with CMV rapidly induce apoptosis to oppose viral growth,[@bib26] and our results are consistent with this finding. In addition, because ROCK inhibitors are known to alter cell adhesion properties and upregulate cell--cell contacts,[@bib54] to clarify if ROCK inhibitors (Y27632, K115) can attenuate the changes induced by CMV infection in cell--cell contact and the barrier function, we infected monolayer hCECs and looked for changes in cell permeability.

hCEC permeability increased immediately after CMV infection ([Figs. 6](#fig6){ref-type="fig"}A, [6](#fig6){ref-type="fig"}B). This increased permeability was attenuated by ROCK inhibitors (Y27632, K115) and NF-κB inhibitor ([Figs. 6](#fig6){ref-type="fig"}A, [6](#fig6){ref-type="fig"}B). This suggests that CMV induced decreased cell--cell contact and that barrier function can be restored with ROCK inhibition or transcriptional inhibition of NF-κB ([Figs. 6](#fig6){ref-type="fig"}A, [6](#fig6){ref-type="fig"}B). Also, hCECs were stained with ZO-1 after CMV infection. [Figures 7](#fig7){ref-type="fig"}A and [7](#fig7){ref-type="fig"}B show that CMV infection significantly impaired cell--cell adhesion, and treatment with ROCK inhibitors significantly restored diminished cell--cell adhesion and cytoskeletal formation. Collectively, ROCK inhibitors showed the potential to protect CMV-infected cells from apoptosis and to maintain cellular integrity.

PSS is characterized by acute and recurrent IOP elevation in unilateral eyes, often accompanied by significant corneal endothelial cell loss; our findings support the hypotheses that dysfunction in hCECs induced by CMV infection can promote TNF-α and its downstream cascade and can trigger severe corneal endothelial cell loss. When the number of corneal endothelial cells has decreased, the condition is irreversible and cannot be treated medically. It has been reported that TNF-α is important in the reactivation of CMV infection.[@bib55]^--^[@bib57] [Figure 4](#fig4){ref-type="fig"} shows that ROCK inhibitors had the potential to alter TNF-α upregulation induced by CMV infection. Thus, ROCK inhibitors could assist in the treatment of corneal endothelial cell loss of CMV-positive PSS patients.

Our study had several limitations. First, although we typically collected the AH at the time of IOP elevation, we could not compare the levels of TNF-α with that at other times or according to the CMV copy number or CMV infection activity. Further investigation will be needed, including prospective studies, to make these comparisons. Second, the number of AH samples was relatively small, so further studies with larger samples will be necessary to analyze the relationship between the number of corneal endothelial cells and cytokine profiles, for example. Third, the ratio of male subjects to female subjects differed in the control and patient groups in this study. It would be ethically difficult to obtain aqueous humor from healthy young subjects without any ocular diseases who are of the same generation as those affected by PSS, and the number of patients undergoing cataract surgery in their same generation was limited. Fourth, AD169/rev is a virus mutant made from AD169 designed to be tropic for endothelial cells, so the virus strain could be stronger than the clinical virus strains collected in the patients' aqueous humor. Though the virulence of the CMV strain in this study may deviate from clinical practice because the infectivity depends on cell types, the aqueous cytokine profile changes, and the decreased number of corneal endothelial cells found in CMV-positive PSS patients corresponds to the results of our in vitro study. For this reason, we suggest that our findings on TNF-α upregulation and apoptotic changes in hCECs mimic clinical changes induced with CMV infection. Fifth, this is a retrospective and in vitro study; thus, further experiments using animal models will be needed to explore whether CMV infection in the anterior chamber may induce TNF-α upregulation or corneal endothelial cell loss in the future. Finally, though we preliminarily compared the number of the corneal endothelial cells between control and CMV--/PSS groups, there was no significant difference between those groups (data not shown), and there should be a study that includes CMV--/PSS patients in the future.

In the present study, we found that TNF-α was upregulated in the AH and in CMV-infected hCECs, which may trigger apoptotic changes in hCECs. Modulation of TNF-α and its downstream cascade could therefore serve as a novel and effective treatment for patients with CMV-positive PSS.
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